Canada-based Husky Injection Molding Systems announced that it has entered into a definitive agreement to acquire Sch?ttli Group, a supplier of medical and closure mold from Switzerland. The sale is expected to close in early December.

Husky says Sch?ttli is one of the global leaders in a number of select medical applications, such as syringes, infusion/transfusion products, diagnostic systems and feminine care items, where its hot runner systems can benefit from. In addition, Sch?ttli's closures business complements Husky's existing closures business by providing additional technology and capacity in both established and growing markets.

"Husky has enjoyed a strong and long-lasting relationship with Sch?ttli and we have long shared a mutual commitment to quality, technology innovation and customer satisfaction," said John Galt, Husky's President and CEO. "Through this acquisition, we will be able to work with the many skilled people at Sch?ttli as one team to deliver more value to customers, particularly in the medical and closures markets. Our goal is to expand our knowledge, expertise, capacity and global footprint so that we can provide the best possible support to customers in these areas of our business."

Following the closing of this transaction, Sch?ttli's headquarter in Diessenhofen, Switzerland, as well as the other facilities in San Dimas, California, and Suzhou, China will become part of Husky's global network of locations.

"As a technical leader with a growing customer base, we are proud of what our team has accomplished and have confidence this relationship will positively benefit customers," said Thomas Anderegg, President and CEO of Sch?ttli. "By joining with Husky we are partnering with a like-minded industry leader to continue providing leading-edge technology, with the advantage of Husky's extensive sales and service network to better support our global customer base. We are excited about this new chapter in our company's history and look forward to the benefits and synergies this acquisition will bring."

Canada-based Husky Injection Molding Systems announced that it has entered into a definitive agreement to acquire Sch?ttli Group, a supplier of medical and closure mold from Switzerland. The sale is expected to close in early December.

Husky says Sch?ttli is one of the global leaders in a number of select medical applications, such as syringes, infusion/transfusion products, diagnostic systems and feminine care items, where its hot runner systems can benefit from. In addition, Sch?ttli's closures business complements Husky's existing closures business by providing additional technology and capacity in both established and growing markets.

"Husky has enjoyed a strong and long-lasting relationship with Sch?ttli and we have long shared a mutual commitment to quality, technology innovation and customer satisfaction," said John Galt, Husky's President and CEO. "Through this acquisition, we will be able to work with the many skilled people at Sch?ttli as one team to deliver more value to customers, particularly in the medical and closures markets. Our goal is to expand our knowledge, expertise, capacity and global footprint so that we can provide the best possible support to customers in these areas of our business."

Following the closing of this transaction, Sch?ttli's headquarter in Diessenhofen, Switzerland, as well as the other facilities in San Dimas, California, and Suzhou, China will become part of Husky's global network of locations.

"As a technical leader with a growing customer base, we are proud of what our team has accomplished and have confidence this relationship will positively benefit customers," said Thomas Anderegg, President and CEO of Sch?ttli. "By joining with Husky we are partnering with a like-minded industry leader to continue providing leading-edge technology, with the advantage of Husky's extensive sales and service network to better support our global customer base. We are excited about this new chapter in our company's history and look forward to the benefits and synergies this acquisition will bring."